James Continenza

Executive Chairman & Chief Executive Officer, Eastman Kodak

Search every verified James Continenza interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. James Continenza, Executive Chairman and CEO of Eastman Kodak, has emphasized the company’s focus on its core businesses of print, film, and chemicals, describing the company as “a chemical company first” and stating that it had “lost its way” before his leadership. He has highlighted efforts to stabilize Kodak’s balance sheet, reduce debt, and improve operational efficiencies, noting that the company reduced net debt by $294 million compared to March 2019. Continenza has also pointed to revenue growth in all segments in 2021 and improvements in gross profit in 2022, attributing these results to cost-cutting, pricing actions, and a strategic plan implemented over the prior four years. In 2020, Continenza announced Kodak’s intention to produce pharmaceutical ingredients, with the U.S. International Development Finance Corporation signing a letter of interest for a potential $765 million loan. He described the loan as repayable over 25 years and said Kodak would repurpose existing buildings at Eastman Business Park to reduce costs. Continenza later stated that the application process had been placed on hold but that Kodak would continue expanding its pharmaceutical business regardless, though the scale and speed would depend on capital availability. He has also discussed investments in digital printing technology, including the release of the Prosper Ultra 520 press, and the construction of a facility to manufacture reagents for health care applications. Continenza has said he is “out” on Kodak’s prior venture into cryptocurrency, stating it is “not what we do.”